Apellis Pharmaceuticals, Inc. (APLS) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Apellis (APLS) Q4 2025: Empaveli Penetration Tops 5%, Signaling Rare Disease Launch Outperformance
February 25, 2026
-
Apellis Pharmaceuticals (APLS) Q3 2025: Empaveli Launch Drives 152 Patient Starts, Sets Stage for Nephrology Ramp
October 30, 2025
-
Apellis (APLS) Q2 2025: Free Goods Hit $13M as Injection Growth Holds, New Kidney Launch Sets Up Second-Half Inflection
July 31, 2025
-
Apellis (APLS) Q1 2025: 4% Injection Growth Masks Channel and Copay Headwinds, Eyes Empaveli Launch
July 06, 2025